Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Ervebo
Regeneron UK Limited
Ebola Virus Disease
1 trial -
Evinacumab
Regeneron UK Limited
Hypercholesterolemia
1 trial -
FDC fianlimab+cemiplimab
Regeneron UK Limited
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Fianlimab
Regeneron UK Limited
Advanced Melanoma
1 trial -
Fianlimab
Regeneron UK Limited
Resectable Non-small Cell Lung Cancer
1 trial -
Fianlimab
Regeneron UK Limited
Advanced Renal Cell Carcinoma (aRCC)
1 trial -
Fianlimab+cemiplimab
Regeneron UK Limited
Melanoma
1 trial -
Gemcitabine
Regeneron UK Limited
Bladder Cancer
1 trial -
Hyperpolarized Xe129
Regeneron UK Limited
Pulmonary Artery Hypertension
1 trial -
ISA101b
Regeneron UK Limited
Squamous Cell Carcinoma of the Oropharynx
2 trials -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Central Retinal Vein Occlusion
1 trial -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Central Serous Chorioretinopathy
1 trial -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Age-Related Macular Degeneration
2 trials -
Itepekimab (SAR440340)
Regeneron UK Limited
Bronchiectasis
1 trial -
Itepekimab (SAR440340)
Regeneron UK Limited
Chronic Rhinosinusitis Without Nasal Polyps
1 trial -
Linvoseltamab
Regeneron UK Limited
Relapsed/Refractory Multiple Myeloma
1 trial -
Linvoseltamab
Regeneron UK Limited
Recurrent Multiple Myeloma
1 trial -
Linvoseltamab
Regeneron UK Limited
Monoclonal Gammopathy of Undetermined Significance (MGUS)
1 trial -
Linvoseltamab
Regeneron UK Limited
Smoldering Multiple Myeloma (SMM)
1 trial -
Linvoseltamab
Regeneron UK Limited
Relapsed/Refractory Systemic Light Chain Amyloidosis
1 trial -
MaaT033 capsule
Regeneron UK Limited
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Mibavademab
Regeneron UK Limited
Functional Hypothalamic Amenorrhea (FHA)
1 trial -
Motixafortide
Regeneron UK Limited
Pancreatic Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources